PT  - JOURNAL ARTICLE
AU  - Hitchings, Matt D.T.
AU  - Ranzani, Otavio T.
AU  - Scaramuzzini Torres, Mario Sergio
AU  - de Oliveira, Silvano Barbosa
AU  - Almiron, Maria
AU  - Said, Rodrigo
AU  - Borg, Ryan
AU  - Schulz, Wade L.
AU  - de Oliveira, Roberto Dias
AU  - da Silva, Patricia Vieira
AU  - de Castro, Daniel Barros
AU  - de Souza Sampaio, Vanderson
AU  - Cláudio de Albuquerque, Bernardino
AU  - Amorim Ramos, Tatyana Costa
AU  - Hauache Fraxe, Shadia Hussami
AU  - da Costa, Cristiano Fernandes
AU  - Naveca, Felipe Gomes
AU  - Siqueira, Andre M.
AU  - de Araújo, Wildo Navegantes
AU  - Andrews, Jason R.
AU  - Cummings, Derek A.T.
AU  - Ko, Albert I.
AU  - Croda, Julio
TI  - Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study
AID  - 10.1101/2021.04.07.21255081
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.07.21255081
4099  - http://medrxiv.org/content/early/2021/04/07/2021.04.07.21255081.short
4100  - http://medrxiv.org/content/early/2021/04/07/2021.04.07.21255081.full
AB  - Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant P.1 emerged in the city of Manaus in late 2020 during a large resurgence of coronavirus disease (COVID-19), and has spread throughout Brazil. The effectiveness of vaccines in settings with widespread P.1 transmission has not been reported.Methods We performed a matched test-negative case-control study to estimate the effectiveness of an inactivated vaccine, CoronaVac, in healthcare workers (HCWs) in Manaus, where P.1 accounted for 75% of genotyped SARS-CoV-2 samples at the peak of its epidemic. Information from electronic surveillance databases was used to select cases of RT-PCR-confirmed SARS-CoV-2 infection and matched test-negative controls from 19 January, 2021 to 25 March, 2021. We used conditional logistic regression to estimate the effectiveness in reducing the odds of primary and secondary outcomes of, respectively, symptomatic and any SARS-CoV-2 infection.Findings Among 53,176 HCWs, 46,884 (88%) received at least one dose of CoronaVac and 2,656 (5%) underwent RT-PCR testing from 19 January, 2021 to 25 March, 2021. Of 2,797 RT-PCR tests, 776 (28%) were positive. 393 and 135 case-control pairs with and without, respectively, symptomatic illness were selected for the matched analyses. Vaccination with at least one dose was associated with a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%; 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, −6.6 - 60.5) in the same time period.Interpretation Administration of at least one dose of CoronaVac showed effectiveness against symptomatic SARS-CoV-2 infection in the setting of epidemic P.1 transmission, underscoring the need to increase vaccination efforts in response to the spread of this variant in Brazil and globally.Funding Pan American Health Organization; Fundação Oswaldo Cruz (Fiocruz); Municipal Health Secretary of ManausCompeting Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful for Pan American Health Organization’s support to the Fundação Vigilância em Saúde from Amazonas State and the Municipal Health Secretary of Manaus in making the databases available for analysis. JC and AS are supported by the Oswaldo Cruz Foundation (Edital Covid-19 - resposta rápida: 48111668950485). OTR is funded by a Sara Borrell fellowship (CD19/00110) from the Instituto de Salud Carlos III. OTR acknowledges support from the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa 2019-2023 Program and from the Generalitat de Catalunya through the CERCA Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee for Research of Federal University of Mato Grosso do Sul (CAAE: 43289221.5.0000.0021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified databases as well as the R codes will be deposited in the repository https://github.com/juliocroda/VebraCOVID-19 https://github.com/juliocroda/VebraCOVID-19